Title: Full Text of HB2584
Official Title: 
Number of Sections: 1
Source: versions - House Amendment 001
Media Type: text/html

================================================================================

Section 1:
Full Text of HB2584 ILGA.GOV HB2584 - 104th General Assembly Rep. Kelly M. CassidyFiled: 3/10/2025   10400HB2584ham001LRB104 08321 BAB 23420 a1AMENDMENT TO HOUSE BILL 2584 2    AMENDMENT NO. ______. Amend House Bill 2584 by replacing 3everything after the enacting clause with the following: 4    "Section 5. The Illinois Insurance Code is amended by 5changing Section 356z.60 as follows: 6    (215 ILCS 5/356z.60)7    Sec. 356z.60. Coverage for abortifacients, hormonal 8therapy, and human immunodeficiency virus pre-exposure 9prophylaxis and post-exposure prophylaxis.10    (a) As used in this Section:11    "Abortifacients" means any medication administered to 12terminate a pregnancy as prescribed or ordered by a health 13care professional.14    "Health care professional" means a physician licensed to 15practice medicine in all of its branches, licensed advanced 16practice registered nurse, or physician assistant.  10400HB2584ham001- 2 -LRB104 08321 BAB 23420 a1    "Hormonal therapy medication" means hormonal treatment 2administered to treat gender dysphoria.3    "Therapeutic equivalent version" means drugs, devices, or 4products that can be expected to have the same clinical effect 5and safety profile when administered to patients under the 6conditions specified in the labeling and that satisfy the 7following general criteria:8        (1) it is approved as safe and effective;9        (2) it is a pharmaceutical equivalent in that it:10            (A) contains identical amounts of the same active 11        drug ingredient in the same dosage form and route of 12        administration; and13            (B) meets compendial or other applicable standards 14        of strength, quality, purity, and identity;15        (3) it is bioequivalent in that:16            (A) it does not present a known or potential 17        bioequivalence problem and it meets an acceptable in 18        vitro standard; or19            (B) if it does present such a known or potential 20        problem, it is shown to meet an appropriate 21        bioequivalence standard;22        (4) it is adequately labeled; and23        (5) it is manufactured in compliance with Current Good 24    Manufacturing Practice regulations adopted by the United 25    States Food and Drug Administration.26    (b) An individual or group policy of accident and health   10400HB2584ham001- 3 -LRB104 08321 BAB 23420 a1insurance amended, delivered, issued, or renewed in this State 2on or after January 1, 2024 shall provide coverage for all 3abortifacients, hormonal therapy medication, human 4immunodeficiency virus pre-exposure prophylaxis, and 5post-exposure prophylaxis drugs approved by the United States 6Food and Drug Administration, and follow-up services related 7to that coverage, including, but not limited to, management of 8side effects, medication self-management or adherence 9counseling, risk reduction strategies, and mental health 10counseling. This coverage shall include drugs approved by the 11United States Food and Drug Administration that are prescribed 12or ordered for off-label use for the purposes described in 13this Section. On or after the effective date of this 14amendatory Act of the 104th General Assembly, this coverage 15shall include pre-PrEP HIV screening, sexually transmitted 16infection screening, kidney function analysis, routine 17laboratory testing, and routine provider visits. 18    (c) The coverage required under subsection (b) is subject 19to the following conditions:20        (1) If the United States Food and Drug Administration 21    has approved one or more therapeutic equivalent versions 22    of an abortifacient drug, a policy is not required to 23    include all such therapeutic equivalent versions in its 24    formulary so long as at least one is included and covered 25    without cost sharing and in accordance with this Section.26        (2) If an individual's attending provider recommends a   10400HB2584ham001- 4 -LRB104 08321 BAB 23420 a1    particular drug approved by the United States Food and 2    Drug Administration based on a determination of medical 3    necessity with respect to that individual, the plan or 4    issuer must defer to the determination of the attending 5    provider and must cover that service or item without cost 6    sharing.7        (3) If a drug is not covered, plans and issuers must 8    have an easily accessible, transparent, and sufficiently 9    expedient process that is not unduly burdensome on the 10    individual or a provider or other individual acting as a 11    patient's authorized representative to ensure coverage 12    without cost sharing.13    The conditions listed under this subsection (c) also apply 14to drugs prescribed for off-label use as abortifacients. 15    (d) Except as otherwise provided in this Section, a policy 16subject to this Section shall not impose a deductible, 17coinsurance, copayment, or any other cost-sharing requirement 18on the coverage provided. The provisions of this subsection do 19not apply to coverage of procedures to the extent such 20coverage would disqualify a high-deductible health plan from 21eligibility for a health savings account pursuant to the 22federal Internal Revenue Code, 26 U.S.C. 223.23    (e) Except as otherwise authorized under this Section, a 24policy shall not impose any restrictions or delays on the 25coverage required under this Section.26    (f) The coverage requirements in this Section for   10400HB2584ham001- 5 -LRB104 08321 BAB 23420 a1abortifacients do not, pursuant to 42 U.S.C. 18054(a)(6), 2apply to a multistate plan that does not provide coverage for 3abortion.4    (g) If the Department concludes that enforcement of any 5coverage requirement of this Section for abortifacients may 6adversely affect the allocation of federal funds to this 7State, the Department may grant an exemption to that 8requirement, but only to the minimum extent necessary to 9ensure the continued receipt of federal funds.10(Source: P.A. 102-1117, eff. 1-13-23; 103-462, eff. 8-4-23.) 11    Section 10. The Prior Authorization Reform Act is amended 12by adding Section 52 as follows: 13    (215 ILCS 200/52 new)14    Sec. 52. Prior authorization for certain prescription 15drugs; prohibited. A health insurance issuer may not require 16prior authorization for the following prescription drug types 17and their therapeutic equivalents approved by the United 18States Food and Drug Administration: human immunodeficiency 19virus pre-exposure prophylaxis and post-exposure prophylaxis 20medication or human immunodeficiency virus treatment 21medication. 22    Section 15. The Illinois Public Aid Code is amended by 23changing Section 5-5.12 and by adding Section 5-54 as follows:   10400HB2584ham001- 6 -LRB104 08321 BAB 23420 a1    (305 ILCS 5/5-5.12)  (from Ch. 23, par. 5-5.12)2    Sec. 5-5.12. Pharmacy payments. 3    (a) Every request submitted by a pharmacy for 4reimbursement under this Article for prescription drugs 5provided to a recipient of aid under this Article shall 6include the name of the prescriber or an acceptable 7identification number as established by the Department.8    (b) Pharmacies providing prescription drugs under this 9Article shall be reimbursed at a rate which shall include a 10professional dispensing fee as determined by the Illinois 11Department, plus the current acquisition cost of the 12prescription drug dispensed. The Illinois Department shall 13update its information on the acquisition costs of all 14prescription drugs no less frequently than every 30 days. 15However, the Illinois Department may set the rate of 16reimbursement for the acquisition cost, by rule, at a 17percentage of the current average wholesale acquisition cost.18    (c) (Blank).19    (d) The Department shall review utilization of narcotic 20medications in the medical assistance program and impose 21utilization controls that protect against abuse. 22    (e) When making determinations as to which drugs shall be 23on a prior approval list, the Department shall include as part 24of the analysis for this determination, the degree to which a 25drug may affect individuals in different ways based on factors   10400HB2584ham001- 7 -LRB104 08321 BAB 23420 a1including the gender of the person taking the medication. 2    (f) The Department shall cooperate with the Department of 3Public Health and the Department of Human Services Division of 4Mental Health in identifying psychotropic medications that, 5when given in a particular form, manner, duration, or 6frequency (including "as needed") in a dosage, or in 7conjunction with other psychotropic medications to a nursing 8home resident or to a resident of a facility licensed under the 9ID/DD Community Care Act or the MC/DD Act, may constitute a 10chemical restraint or an "unnecessary drug" as defined by the 11Nursing Home Care Act or Titles XVIII and XIX of the Social 12Security Act and the implementing rules and regulations. The 13Department shall require prior approval for any such 14medication prescribed for a nursing home resident or to a 15resident of a facility licensed under the ID/DD Community Care 16Act or the MC/DD Act, that appears to be a chemical restraint 17or an unnecessary drug. The Department shall consult with the 18Department of Human Services Division of Mental Health in 19developing a protocol and criteria for deciding whether to 20grant such prior approval. 21    (g) The Department may by rule provide for reimbursement 22of the dispensing of a 90-day supply of a generic or brand 23name, non-narcotic maintenance medication in circumstances 24where it is cost effective. 25    (g-5) On and after July 1, 2012, the Department may 26require the dispensing of drugs to nursing home residents be   10400HB2584ham001- 8 -LRB104 08321 BAB 23420 a1in a 7-day supply or other amount less than a 31-day supply. 2The Department shall pay only one dispensing fee per 31-day 3supply. 4    (h) Effective July 1, 2011, the Department shall 5discontinue coverage of select over-the-counter drugs, 6including analgesics and cough and cold and allergy 7medications. 8    (h-5) The On and after July 1, 2012, the Department shall 9impose utilization controls, including, but not limited to, 10prior approval on specialty drugs, oncolytic drugs, drugs for 11the treatment of HIV or AIDS, immunosuppressant drugs, and 12biological products in order to maximize savings on these 13drugs. The Department may adjust payment methodologies for 14non-pharmacy billed drugs in order to incentivize the 15selection of lower-cost drugs. For drugs for the treatment of 16AIDS, the Department shall take into consideration the 17potential for non-adherence by certain populations, and shall 18develop protocols with organizations or providers primarily 19serving those with HIV/AIDS, as long as such measures intend 20to maintain cost neutrality with other utilization management 21controls such as prior approval. For hemophilia, the 22Department shall develop a program of utilization review and 23control which may include, in the discretion of the 24Department, prior approvals. The Department may impose special 25standards on providers that dispense blood factors which shall 26include, in the discretion of the Department, staff training   10400HB2584ham001- 9 -LRB104 08321 BAB 23420 a1and education; patient outreach and education; case 2management; in-home patient assessments; assay management; 3maintenance of stock; emergency dispensing timeframes; data 4collection and reporting; dispensing of supplies related to 5blood factor infusions; cold chain management and packaging 6practices; care coordination; product recalls; and emergency 7clinical consultation. The Department may require patients to 8receive a comprehensive examination annually at an appropriate 9provider in order to be eligible to continue to receive blood 10factor. 11    (i) On and after July 1, 2012, the Department shall reduce 12any rate of reimbursement for services or other payments or 13alter any methodologies authorized by this Code to reduce any 14rate of reimbursement for services or other payments in 15accordance with Section 5-5e. 16    (j) On and after July 1, 2012, the Department shall impose 17limitations on prescription drugs such that the Department 18shall not provide reimbursement for more than 4 prescriptions, 19including 3 brand name prescriptions, for distinct drugs in a 2030-day period, unless prior approval is received for all 21prescriptions in excess of the 4-prescription limit. Drugs in 22the following therapeutic classes shall not be subject to 23prior approval as a result of the 4-prescription limit: 24immunosuppressant drugs, oncolytic drugs, anti-retroviral 25drugs, and, on or after July 1, 2014, antipsychotic drugs. On 26or after July 1, 2014, the Department may exempt children with   10400HB2584ham001- 10 -LRB104 08321 BAB 23420 a1complex medical needs enrolled in a care coordination entity 2contracted with the Department to solely coordinate care for 3such children, if the Department determines that the entity 4has a comprehensive drug reconciliation program.5    (k) No medication therapy management program implemented 6by the Department shall be contrary to the provisions of the 7Pharmacy Practice Act.8    (l) Any provider enrolled with the Department that bills 9the Department for outpatient drugs and is eligible to enroll 10in the federal Drug Pricing Program under Section 340B of the 11federal Public Health Service Act shall enroll in that 12program. No entity participating in the federal Drug Pricing 13Program under Section 340B of the federal Public Health 14Service Act may exclude fee-for-service Medicaid from their 15participation in that program, however, entities defined in 16Section 1905(l)(2)(B) of the Social Security Act are excluded 17from this requirement. This subsection does not apply to 18outpatient drugs billed to Medicaid managed care 19organizations. 20(Source: P.A. 102-558, eff. 8-20-21; 102-778, eff. 7-1-22.) 21    (305 ILCS 5/5-54 new)22    Sec. 5-54. Prior authorization for certain prescription 23drugs; prohibited. The fee-for-service medical assistance 24program and a Medicaid managed care organization may not 25require prior authorization for the following prescription   10400HB2584ham001- 11 -LRB104 08321 BAB 23420 a1drug types and their therapeutic equivalents approved by the 2United States Food and Drug Administration: human 3immunodeficiency virus pre-exposure prophylaxis and 4post-exposure prophylaxis medication or human immunodeficiency 5virus treatment medication. 6    Section 99. Effective date. This Act takes effect January 71, 2027.".


================================================================================

Raw Text:
Full Text of HB2584 ILGA.GOV HB2584 - 104th General Assembly Rep. Kelly M. CassidyFiled: 3/10/2025   10400HB2584ham001LRB104 08321 BAB 23420 a1AMENDMENT TO HOUSE BILL 2584 2    AMENDMENT NO. ______. Amend House Bill 2584 by replacing 3everything after the enacting clause with the following: 4    "Section 5. The Illinois Insurance Code is amended by 5changing Section 356z.60 as follows: 6    (215 ILCS 5/356z.60)7    Sec. 356z.60. Coverage for abortifacients, hormonal 8therapy, and human immunodeficiency virus pre-exposure 9prophylaxis and post-exposure prophylaxis.10    (a) As used in this Section:11    "Abortifacients" means any medication administered to 12terminate a pregnancy as prescribed or ordered by a health 13care professional.14    "Health care professional" means a physician licensed to 15practice medicine in all of its branches, licensed advanced 16practice registered nurse, or physician assistant.  10400HB2584ham001- 2 -LRB104 08321 BAB 23420 a1    "Hormonal therapy medication" means hormonal treatment 2administered to treat gender dysphoria.3    "Therapeutic equivalent version" means drugs, devices, or 4products that can be expected to have the same clinical effect 5and safety profile when administered to patients under the 6conditions specified in the labeling and that satisfy the 7following general criteria:8        (1) it is approved as safe and effective;9        (2) it is a pharmaceutical equivalent in that it:10            (A) contains identical amounts of the same active 11        drug ingredient in the same dosage form and route of 12        administration; and13            (B) meets compendial or other applicable standards 14        of strength, quality, purity, and identity;15        (3) it is bioequivalent in that:16            (A) it does not present a known or potential 17        bioequivalence problem and it meets an acceptable in 18        vitro standard; or19            (B) if it does present such a known or potential 20        problem, it is shown to meet an appropriate 21        bioequivalence standard;22        (4) it is adequately labeled; and23        (5) it is manufactured in compliance with Current Good 24    Manufacturing Practice regulations adopted by the United 25    States Food and Drug Administration.26    (b) An individual or group policy of accident and health   10400HB2584ham001- 3 -LRB104 08321 BAB 23420 a1insurance amended, delivered, issued, or renewed in this State 2on or after January 1, 2024 shall provide coverage for all 3abortifacients, hormonal therapy medication, human 4immunodeficiency virus pre-exposure prophylaxis, and 5post-exposure prophylaxis drugs approved by the United States 6Food and Drug Administration, and follow-up services related 7to that coverage, including, but not limited to, management of 8side effects, medication self-management or adherence 9counseling, risk reduction strategies, and mental health 10counseling. This coverage shall include drugs approved by the 11United States Food and Drug Administration that are prescribed 12or ordered for off-label use for the purposes described in 13this Section. On or after the effective date of this 14amendatory Act of the 104th General Assembly, this coverage 15shall include pre-PrEP HIV screening, sexually transmitted 16infection screening, kidney function analysis, routine 17laboratory testing, and routine provider visits. 18    (c) The coverage required under subsection (b) is subject 19to the following conditions:20        (1) If the United States Food and Drug Administration 21    has approved one or more therapeutic equivalent versions 22    of an abortifacient drug, a policy is not required to 23    include all such therapeutic equivalent versions in its 24    formulary so long as at least one is included and covered 25    without cost sharing and in accordance with this Section.26        (2) If an individual's attending provider recommends a   10400HB2584ham001- 4 -LRB104 08321 BAB 23420 a1    particular drug approved by the United States Food and 2    Drug Administration based on a determination of medical 3    necessity with respect to that individual, the plan or 4    issuer must defer to the determination of the attending 5    provider and must cover that service or item without cost 6    sharing.7        (3) If a drug is not covered, plans and issuers must 8    have an easily accessible, transparent, and sufficiently 9    expedient process that is not unduly burdensome on the 10    individual or a provider or other individual acting as a 11    patient's authorized representative to ensure coverage 12    without cost sharing.13    The conditions listed under this subsection (c) also apply 14to drugs prescribed for off-label use as abortifacients. 15    (d) Except as otherwise provided in this Section, a policy 16subject to this Section shall not impose a deductible, 17coinsurance, copayment, or any other cost-sharing requirement 18on the coverage provided. The provisions of this subsection do 19not apply to coverage of procedures to the extent such 20coverage would disqualify a high-deductible health plan from 21eligibility for a health savings account pursuant to the 22federal Internal Revenue Code, 26 U.S.C. 223.23    (e) Except as otherwise authorized under this Section, a 24policy shall not impose any restrictions or delays on the 25coverage required under this Section.26    (f) The coverage requirements in this Section for   10400HB2584ham001- 5 -LRB104 08321 BAB 23420 a1abortifacients do not, pursuant to 42 U.S.C. 18054(a)(6), 2apply to a multistate plan that does not provide coverage for 3abortion.4    (g) If the Department concludes that enforcement of any 5coverage requirement of this Section for abortifacients may 6adversely affect the allocation of federal funds to this 7State, the Department may grant an exemption to that 8requirement, but only to the minimum extent necessary to 9ensure the continued receipt of federal funds.10(Source: P.A. 102-1117, eff. 1-13-23; 103-462, eff. 8-4-23.) 11    Section 10. The Prior Authorization Reform Act is amended 12by adding Section 52 as follows: 13    (215 ILCS 200/52 new)14    Sec. 52. Prior authorization for certain prescription 15drugs; prohibited. A health insurance issuer may not require 16prior authorization for the following prescription drug types 17and their therapeutic equivalents approved by the United 18States Food and Drug Administration: human immunodeficiency 19virus pre-exposure prophylaxis and post-exposure prophylaxis 20medication or human immunodeficiency virus treatment 21medication. 22    Section 15. The Illinois Public Aid Code is amended by 23changing Section 5-5.12 and by adding Section 5-54 as follows:   10400HB2584ham001- 6 -LRB104 08321 BAB 23420 a1    (305 ILCS 5/5-5.12)  (from Ch. 23, par. 5-5.12)2    Sec. 5-5.12. Pharmacy payments. 3    (a) Every request submitted by a pharmacy for 4reimbursement under this Article for prescription drugs 5provided to a recipient of aid under this Article shall 6include the name of the prescriber or an acceptable 7identification number as established by the Department.8    (b) Pharmacies providing prescription drugs under this 9Article shall be reimbursed at a rate which shall include a 10professional dispensing fee as determined by the Illinois 11Department, plus the current acquisition cost of the 12prescription drug dispensed. The Illinois Department shall 13update its information on the acquisition costs of all 14prescription drugs no less frequently than every 30 days. 15However, the Illinois Department may set the rate of 16reimbursement for the acquisition cost, by rule, at a 17percentage of the current average wholesale acquisition cost.18    (c) (Blank).19    (d) The Department shall review utilization of narcotic 20medications in the medical assistance program and impose 21utilization controls that protect against abuse. 22    (e) When making determinations as to which drugs shall be 23on a prior approval list, the Department shall include as part 24of the analysis for this determination, the degree to which a 25drug may affect individuals in different ways based on factors   10400HB2584ham001- 7 -LRB104 08321 BAB 23420 a1including the gender of the person taking the medication. 2    (f) The Department shall cooperate with the Department of 3Public Health and the Department of Human Services Division of 4Mental Health in identifying psychotropic medications that, 5when given in a particular form, manner, duration, or 6frequency (including "as needed") in a dosage, or in 7conjunction with other psychotropic medications to a nursing 8home resident or to a resident of a facility licensed under the 9ID/DD Community Care Act or the MC/DD Act, may constitute a 10chemical restraint or an "unnecessary drug" as defined by the 11Nursing Home Care Act or Titles XVIII and XIX of the Social 12Security Act and the implementing rules and regulations. The 13Department shall require prior approval for any such 14medication prescribed for a nursing home resident or to a 15resident of a facility licensed under the ID/DD Community Care 16Act or the MC/DD Act, that appears to be a chemical restraint 17or an unnecessary drug. The Department shall consult with the 18Department of Human Services Division of Mental Health in 19developing a protocol and criteria for deciding whether to 20grant such prior approval. 21    (g) The Department may by rule provide for reimbursement 22of the dispensing of a 90-day supply of a generic or brand 23name, non-narcotic maintenance medication in circumstances 24where it is cost effective. 25    (g-5) On and after July 1, 2012, the Department may 26require the dispensing of drugs to nursing home residents be   10400HB2584ham001- 8 -LRB104 08321 BAB 23420 a1in a 7-day supply or other amount less than a 31-day supply. 2The Department shall pay only one dispensing fee per 31-day 3supply. 4    (h) Effective July 1, 2011, the Department shall 5discontinue coverage of select over-the-counter drugs, 6including analgesics and cough and cold and allergy 7medications. 8    (h-5) The On and after July 1, 2012, the Department shall 9impose utilization controls, including, but not limited to, 10prior approval on specialty drugs, oncolytic drugs, drugs for 11the treatment of HIV or AIDS, immunosuppressant drugs, and 12biological products in order to maximize savings on these 13drugs. The Department may adjust payment methodologies for 14non-pharmacy billed drugs in order to incentivize the 15selection of lower-cost drugs. For drugs for the treatment of 16AIDS, the Department shall take into consideration the 17potential for non-adherence by certain populations, and shall 18develop protocols with organizations or providers primarily 19serving those with HIV/AIDS, as long as such measures intend 20to maintain cost neutrality with other utilization management 21controls such as prior approval. For hemophilia, the 22Department shall develop a program of utilization review and 23control which may include, in the discretion of the 24Department, prior approvals. The Department may impose special 25standards on providers that dispense blood factors which shall 26include, in the discretion of the Department, staff training   10400HB2584ham001- 9 -LRB104 08321 BAB 23420 a1and education; patient outreach and education; case 2management; in-home patient assessments; assay management; 3maintenance of stock; emergency dispensing timeframes; data 4collection and reporting; dispensing of supplies related to 5blood factor infusions; cold chain management and packaging 6practices; care coordination; product recalls; and emergency 7clinical consultation. The Department may require patients to 8receive a comprehensive examination annually at an appropriate 9provider in order to be eligible to continue to receive blood 10factor. 11    (i) On and after July 1, 2012, the Department shall reduce 12any rate of reimbursement for services or other payments or 13alter any methodologies authorized by this Code to reduce any 14rate of reimbursement for services or other payments in 15accordance with Section 5-5e. 16    (j) On and after July 1, 2012, the Department shall impose 17limitations on prescription drugs such that the Department 18shall not provide reimbursement for more than 4 prescriptions, 19including 3 brand name prescriptions, for distinct drugs in a 2030-day period, unless prior approval is received for all 21prescriptions in excess of the 4-prescription limit. Drugs in 22the following therapeutic classes shall not be subject to 23prior approval as a result of the 4-prescription limit: 24immunosuppressant drugs, oncolytic drugs, anti-retroviral 25drugs, and, on or after July 1, 2014, antipsychotic drugs. On 26or after July 1, 2014, the Department may exempt children with   10400HB2584ham001- 10 -LRB104 08321 BAB 23420 a1complex medical needs enrolled in a care coordination entity 2contracted with the Department to solely coordinate care for 3such children, if the Department determines that the entity 4has a comprehensive drug reconciliation program.5    (k) No medication therapy management program implemented 6by the Department shall be contrary to the provisions of the 7Pharmacy Practice Act.8    (l) Any provider enrolled with the Department that bills 9the Department for outpatient drugs and is eligible to enroll 10in the federal Drug Pricing Program under Section 340B of the 11federal Public Health Service Act shall enroll in that 12program. No entity participating in the federal Drug Pricing 13Program under Section 340B of the federal Public Health 14Service Act may exclude fee-for-service Medicaid from their 15participation in that program, however, entities defined in 16Section 1905(l)(2)(B) of the Social Security Act are excluded 17from this requirement. This subsection does not apply to 18outpatient drugs billed to Medicaid managed care 19organizations. 20(Source: P.A. 102-558, eff. 8-20-21; 102-778, eff. 7-1-22.) 21    (305 ILCS 5/5-54 new)22    Sec. 5-54. Prior authorization for certain prescription 23drugs; prohibited. The fee-for-service medical assistance 24program and a Medicaid managed care organization may not 25require prior authorization for the following prescription   10400HB2584ham001- 11 -LRB104 08321 BAB 23420 a1drug types and their therapeutic equivalents approved by the 2United States Food and Drug Administration: human 3immunodeficiency virus pre-exposure prophylaxis and 4post-exposure prophylaxis medication or human immunodeficiency 5virus treatment medication. 6    Section 99. Effective date. This Act takes effect January 71, 2027.".